Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

AIMS: Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP 1 and 4 trials. MATERIALS AND METHODS: STEP 1 and 4 were phase III, 68‐week, placebo‐controlled trials of once‐weekly semaglutide 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosiborod, Mikhail N., Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Khalid, Usman, Kushner, Robert, Rubino, Domenica M., Zeuthen, Niels, Verma, Subodh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092593/
https://www.ncbi.nlm.nih.gov/pubmed/36200477
http://dx.doi.org/10.1111/dom.14890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092593/
https://www.ncbi.nlm.nih.gov/pubmed/36200477
http://dx.doi.org/10.1111/dom.14890

Ejemplares similares